What is Nicorandil
Nicorandil is an antianginal medication with a unique dual mechanism of action: it functions both as a nitrate (donating nitric oxide) and as an ATP-sensitive potassium channel opener, providing balanced coronary and peripheral vasodilation. 1
Mechanism of Action
Nicorandil works through two distinct pathways 2, 3:
- Nitrate component: Donates nitric oxide, causing venodilation and reducing preload (similar to traditional nitrates)
- Potassium channel activation: Opens ATP-sensitive potassium (K-ATP) channels in vascular smooth muscle, causing arterial vasodilation and reducing afterload
This dual mechanism distinguishes nicorandil from conventional antianginal drugs, as it dilates both coronary resistance and conductive vessels while having minimal effects on heart rate, blood pressure, or cardiac contractility at therapeutic doses 4, 5.
Clinical Indications
Chronic Stable Angina
Nicorandil is positioned as a second-line or add-on antianginal agent when beta-blockers and/or calcium channel blockers provide inadequate symptom control. 6
According to the 2024 ESC guidelines 6:
- IIa recommendation (Level B): Should be considered as add-on therapy in patients with inadequate symptom control on beta-blockers and/or CCBs
- May be considered as part of initial treatment in properly selected patients (IIb recommendation)
The 2012 ESC Heart Failure guidelines 7 note that nicorandil may be considered in heart failure patients who cannot tolerate beta-blockers for angina relief, though its safety in heart failure remains uncertain (IIb recommendation, Level C).
Outcomes Data
The IONA trial demonstrated that nicorandil reduced a composite endpoint of cardiovascular death, nonfatal MI, or unplanned hospitalization for chest pain 1. However, critically, this benefit was driven primarily by reduced hospitalizations for unstable angina—not by reductions in the most important outcomes of cardiovascular mortality or myocardial infarction 1. Unexpectedly, nicorandil did not improve chronic stable angina symptoms in this study 1.
A larger beneficial effect was observed in a propensity-matched cohort of 5,115 Japanese patients with chronic stable angina followed for 7 years 1.
Adverse Effects
Common Side Effects
The main adverse effects are 1:
- Headache (most common, leading to 39% withdrawal rate in IONA trial)
- Reflux
- Tachycardia
- Facial flushing
- Hypotension
Serious Adverse Effects
Rarely but importantly, nicorandil can cause serious skin, mucosal, and eye ulceration 1. This is a unique and potentially severe complication that requires vigilance.
The concomitant use of nicorandil with aspirin may increase the risk of gastrointestinal ulcers, perforations, and hemorrhage 1. Recent FAERS data confirms significant associations with gastrointestinal adverse events, particularly in elderly patients, with most events occurring within 1 week of initiation 8.
Dosing Strategy to Minimize Side Effects
To minimize headache, start with a low dose (5 mg twice daily) and titrate upward 9. The recommended therapeutic regimen is 10-20 mg twice daily 9.
Important Clinical Considerations
Drug Combinations
- Do NOT combine nicorandil with other second-line agents (ivabradine, ranolazine) due to unknown safety 7
- Do NOT combine with long-acting nitrates due to lack of additional efficacy 7
- Exercise caution when combining with aspirin due to increased GI bleeding risk 1
Advantages Over Traditional Nitrates
Unlike conventional nitrates, nicorandil does not develop tolerance or cross-tolerance to other nitrates 5. This represents a significant clinical advantage for long-term therapy.
Special Populations
The drug appears particularly effective in elderly patients and those with diabetes mellitus and coronary heart disease, improving angina symptoms and vascular endothelial function 10. However, elderly patients (>65 years) also show higher rates of gastrointestinal adverse events 8.
Availability
Note: Nicorandil is currently unavailable in the United States 11, though it is widely used in Europe and Asia.